Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece

被引：0
|
作者：
Tzanetakos, C. [1 ]
Kourlaba, G. [2 ]
Hatzikou, M. [3 ]
Antoniou, C. [4 ]
Ioannides, D. [5 ]
Lefaki, I. [6 ]
Petridis, A. [7 ]
Rigopoulos, D. [8 ]
Roussaki-Schulze, V. [9 ]
Sotiriadis, D. [10 ]
Maniadakis, N. [1 ]
机构：
[1] Natl Sch Publ Hlth, Hlth Serv Org & Management, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Collaborat Ctr Clin Epidemiol & Outcomes Res CLEO, Athens, Greece
[3] Novartis Hellas SACI SA, Athens, Greece
[4] Univ Athens, Hosp Venereol Dermatol Dis A Syggros, Athens, Greece
[5] Aristoteleio Univ Thessaloniki, Hosp Skin & Venereal Dis, Thessaloniki, Greece
[6] Hosp Skin & Venereal Dis, Dermatol Clin, Thessaloniki, Greece
[7] Hosp Venereol Dermatol Dis A Syggros, Dermatol Clin, Athens, Greece
[8] Univ Athens, Attikon Univ Hosp Athens, Athens, Greece
[9] Univ Thessaly, Univ Hosp Larissa, Larisa, Greece
[10] Aristoteleio Univ Thessaloniki, Gen Hosp Thessaloniki PAPAGEORGIOU, Thessaloniki, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
cost-effectiveness; plaque psoriasis; secukinumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE
    Brazier, N.
    Pan, F.
    Shear, N.
    Jivraj, F.
    Schenkel, B.
    Brown, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [22] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB COMPA RED WITH ETANERCEPT FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COSTA RICA
    Obando, C. A.
    Desanvicente-Celis, Z.
    Herrera, J. A.
    Moreira, M.
    De Castro, J.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A607 - A607
  • [23] IMPACT OF DOSE ESCALATION ON AVERAGE COST AND COST-EFFECTIVENESS OF ANTI-TNF AND USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN
    Ziegler, F.
    Apol, E.
    Egeberg, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S450 - S450
  • [24] COST-EFFECTIVENESS OF SECUKINUMAB IN MODERATE TO SEVERE PSORIASIS COMPARED WITH OTHER BIOLOGICS IN GERMANY
    Graham, C. N.
    McBride, D.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    Augustin, M.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A157 - A157
  • [25] COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL
    Suzuki, C.
    Lopes, N.
    Tozato, C.
    Gilloteau, I
    Graham, C. N.
    [J]. VALUE IN HEALTH, 2018, 21 : S240 - S240
  • [26] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [27] Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry
    Egeberg, A.
    Iversen, L.
    Gniadecki, R.
    Hvid, L.
    Dam, T. N.
    Bryld, L. E.
    Skov, L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : 1183 - 1187
  • [28] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [29] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [30] Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis
    Martin, Silas
    Feldman, Steven R.
    Augustin, Matthias
    Szapary, Philippe
    Schenkel, Brad
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (03) : 138 - 143
12345